


Canada

VA HEALTH CARE ATLAS FY-2000

Mexico

Gulf of Mexico



**Diagnostic Codes Used to Define Cohort
(Substance Abuse)**

ICD-9 code	Description
291	ALCOHOLIC PSYCHOSES*
2910	ALCOHOL WITHDRAWAL DELIRIUM
2911	ALCOHOL AMNESTIC SYNDROME
2912	OTHER ALCOHOLIC DEMENTIA
29120	DEMENTIA ASSOCIATED WITH ALCOHOLISM UNCPESIFIED - DO NOT USE
29121	DEMENTIA ASSOCIATED WITH ALCOHOLISM MILD - DO NOT USE
29122	DEMENTIA ASSOCIATED WITH ALCOHOLISM MODERATE - DO NOT USE
29123	DEMENTIA ASSOCIATED WITH ALCOHOLISM SEVERE - DO NOT USE
2913	ALCOHOL WITHDRAWAL HALLUCINOSIS
2914	IDIOSYNCRATIC ALCOHOL INTOXICATION
2915	ALCOHOLIC JEALOUSY
2918	OTHER SPECIFIED ALCOHOLIC PSYCHOSIS
29181	ALCOHOL WITHDRAWAL
29189	OTHER SPECIFIED ALCOHOLIC PSYCHOSIS, NOT ELSEWHERE CLASSIFIED
2919	UNSPECIFIED ALCOHOLIC PSYCHOSIS
292	DRUG PSYCHOSES*
2920	DRUG WITHDRAWAL SYNDROME
2921	DRUG PARANOID/HALLUCINOS*
29211	DRUG-INDUCED ORGANIC DELUSIONAL SYNDROME
29212	DRUG-INDUCED HALLUCINOSIS
2922	PATHOLOGICAL DRUG INTOXICATION
2928	OTHER DRUG MENTAL DIS*
29281	DRUG-INDUCED DELIRIUM
29282	DRUG-INDUCED DEMENTIA
29283	DRUG-INDUCED AMNESTIC SYNDROME
29284	DRUG-INDUCED ORGANIC AFFECTIVE SYNDROME
29289	OTHER SPECIFIED DRUG-INDUCED MENTAL DISORDERS
2929	UNSPECIFIED DRUG-INDUCED MENTAL DISORDER
303	ALCOHOL DEPENDENCE SYNDR*

Substance Abuse

ICD-9 code	Description
3030	AC ALCOHOL INTOXICATION*
30300	ACUTE ALCOHOLIC INTOXICATION IN ALCOHOLISM, UNSPECIFIED DRINKING BEHA
30301	ACUTE ALCOHOLIC INTOXICATION IN ALCOHOLISM, CONTINUOUS DRINKING BEHAV
30302	ACUTE ALCOHOLIC INTOXICATION IN ALCOHOLISM, EPISODIC DRINKING BEHAVIO
30303	ACUTE ALCOHOLIC INTOXICATION IN ALCOHOLISM, IN REMISSION
3039	ALCOHOL DEPEND NEC/NOS*
30390	OTHER AND UNSPECIFIED ALCOHOL DEPENDENCE, UNSPECIFIED DRINKING BEHAVI
30391	OTHER AND UNSPECIFIED ALCOHOL DEPENDENCE, CONTINUOUS DRINKING BEHAVIO
30392	OTHER AND UNSPECIFIED ALCOHOL DEPENDENCE, EPISODIC DRINKING BEHAVIOR
30393	OTHER AND UNSPECIFIED ALCOHOL DEPENDENCE, IN REMISSION
304	DRUG DEPENDENCE*
3040	OPIOID TYPE DEPENDENCE-DO NOT USE
30400	OPIOID TYPE DEPENDENCE UNSPECIFIED
304000	HEROIN DEPENDECE UNSPECIFIED - DO NOT USE
304001	METHADONE DEPENDECE UNSPECIFIED - DO NOT USE
304002	MORPHINE DEPENDECE UNSPECIFIED - DO NOT USE
304003	OPIUM DEPENDECE UNSPECIFIED - DO NOT USE
304009	OTHER OPIOD DEPENDECE UNSPECIFIED - DO NOT USE
30401	OPIOID TYPE DEPENDENCE CONTINUOUS
304010	HEROIN DEPENDECE CONTINUOUS - DO NOT USE
304011	METHADONE DEPENDECE CONTINUOUS - DO NOT USE
304012	MORPHINE DEPENDECE CONTINUOUS - DO NOT USE
304013	OPIUM DEPENDECE CONTINUOUS - DO NOT USE
304019	OTHER OPIOD DEPENDECE CONTINUOUS - DO NOT USE
30402	OPIOID TYPE DEPENDENCE EPISODIC
304020	HEROIN DEPENDECE EPISODIC - DO NOT USE
304021	METHADONE DEPENDECE EPISODIC - DO NOT USE
304022	MORPHINE DEPENDECE EPISODIC - DO NOT USE
304023	OPIUM DEPENDECE EPISODIC - DO NOT USE
304029	OTHER OPIOD DEPENDECE EPISODIC - DO NOT USE
30403	OPIOID TYPE DEPENDENCE IN REMISSION
304030	HEROIN DEPENDECE REMISSION - DO NOT USE
304031	METHADONE DEPENDECE REMISSION - DO NOT USE
304032	MORPHINE DEPENDECE REMISSION - DO NOT USE

ICD-9 code	Description
304033	OPIUM DEPENDECE REMISSION - DO NOT USE
304039	OTHER OPIOD DEPENDECE REMISSION - DO NOT USE
30409	OTHER OPIOID TYPE DEPENDENCE, NOT ELSEWHERE CLASSIFIED
3041	BARBITURATE/SIMILAR ACTING SEDATIVE/HYPNOTIC DEPENDENCE - DO NOT
30410	BARBITURATE AND SIMILARLY ACTING SEDATIVE OR HYPNOTIC DEPENDENCE UNSP
304100	CHLORAL HYDRATE DEPENDENCE UNSPECIFIED - DO NOT USE
304101	LIBRIUM DEPENDENCE UNSPECIFIED - DO NOT USE
304102	MEPROBAMATE DEPENDENCE UNSPECIFIED - DO NOT USE
304103	NULUDAR METHYPRYLOME DEPENDENCE UNSPECIFIED - DO NOT USE
304104	PARALDEHYDE DEPENDENCE UNSPECIFIED - DO NOT USE
304105	PLACIDYL ETHCHORUYNOL DEPENDENCE UNSPECIFIED - DO NOT USE
304106	VALIUM DIAZEPAM DEPENDENCE UNSPECIFIED - DO NOT USE
304107	DORIDEN GLUTETHIMIDE DEPENDENCE UNSPECIFIED - DO NOT USE
304108	BARBITURATES DEPENDENCE UNSPECIFIED - DO NOT USE
304109	OTHER SEDATIVE OR HYPNOTIC DEPENDENCE UNSPECIFIED - DO NOT USE
30411	BARBITURATE AND SIMILARLY ACTING SEDATIVE OR HYPNOTIC DEPENDENCE CONT
304110	CHLORAL HYDRATE DEPENDENCE CONTINUOUS - DO NOT USE
304111	LIBRIUM DEPENDENCE CONTINUOUS - DO NOT USE
304112	MEPROBAMATE DEPENDENCE CONTINUOUS - DO NOT USE
304113	NULUDAR METHYPRYLOME DEPENDENCE CONTINUOUS - DO NOT USE
304114	PARALDEHYDE DEPENDENCE CONTINUOUS - DO NOT USE
304115	PLACIDYL ETHCHORUYNOL DEPENDENCE CONTINUOUS - DO NOT USE
304116	VALIUM DIAZEPAM DEPENDENCE CONTINUOUS - DO NOT USE
304117	DORIDEN GLUTETHIMIDE DEPENDENCE CONTINUOUS - DO NOT USE
304118	BARBITURATES DEPENDENCE CONTINUOUS - DO NOT USE
304119	OTHER SEDATIVE OR HYPNOTIC DEPENDENCE CONTINUOUS - DO NOT USE
30412	BARBITURATE AND SIMILARLY ACTING SEDATIVE OR HYPNOTIC DEPENDENCE EPIS
304120	CHLORAL HYDRATE EPISODIC CONTINUOUS - DO NOT USE
304121	LIBRIUM DEPENDENCE EPISODIC - DO NOT USE
304122	MEPROBAMATE DEPENDENCE EPISODIC - DO NOT USE
304123	NULUDAR METHYPRYLOME DEPENDENCE EPISODIC - DO NOT USE
304124	PARALDEHYDE DEPENDENCE EPISODIC - DO NOT USE
304125	PLACIDYL ETHCHORUYNOL DEPENDENCE EPISODIC - DO NOT USE
304126	VALIUM DIAZEPAM DEPENDENCE EPISODIC - DO NOT USE

Substance Abuse

ICD-9 code	Description
304127	DORIDEN GLUTETHIMIDE DEPENDENCE EPISODIC - DO NOT USE
304128	BARBITURATES DEPENDENCE EPISODIC - DO NOT USE
304129	OTHER SEDATIVE OR HYPNOTIC DEPENDENCE EPISODIC - DO NOT USE
30413	BARBITURATE AND SIMILARLY ACTING SEDATIVE OR HYPNOTIC DEPENDENCE IN R
304130	CHLORAL HYDRATE REMISSION CONTINUOUS - DO NOT USE
304131	LIBRIUM DEPENDENCE REMISSION - DO NOT USE
304132	MEPROBAMATE DEPENDENCE REMISSION - DO NOT USE
304133	NULUDAR METHYPRYLOME DEPENDENCE REMISSION - DO NOT USE
304134	PARALDEHYDE DEPENDENCE REMISSION - DO NOT USE
304135	PLACIDYL ETHCHORUYNOL DEPENDENCE REMISSION - DO NOT USE
304136	VALIUM DIAZEPAM DEPENDENCE REMISSION - DO NOT USE
304137	DORIDEN GLUTETHIMIDE DEPENDENCE REMISSION - DO NOT USE
304138	BARBITURATES DEPENDENCE REMISSION - DO NOT USE
304139	OTHER SEDATIVE OR HYPNOTIC DEPENDENCE REMISSION - DO NOT USE
30414	PARALDEHYDE DEPENDENCE
30415	PLACIDYL, ETHCHLORUYNOL DEPENDENCE
30416	VALIUM, DIAZEPAM DEPENDENCE
30417	DORIDEN, GLUTETHIMIDE DEPENDENCE
30418	BARBITURATES DEPENDENCE
30419	OTHER SEDATIVE OR HYPNOTIC DEPENDENCE, NOT ELSEWHERE CLASSIFIED
3042	COCAINE DEPENDENCE - DO NOT USE
30420	COCAINE DEPENDENCE, UNSPECIFIED USE
30421	COCAINE DEPENDENCE, CONTINUOUS USE
30422	COCAINE DEPENDENCE, EPISODIC USE
30423	COCAINE DEPENDENCE, IN REMISSION
3043	CANNABIS DEPENDENCE - DO NOT USE
30430	CANNABIS DEPENDENCE UNSPECIFIED
304300	MARIJUANA DEPENDENCE UNSPECIFIED
304309	OTHER CANNABIS DEPENDENCE UNSPECIFIED
30431	CANNABIS DEPENDENCE, CONTINUOUS USE
304310	MARIJUANA DEPENDENCE CONTINUOUS
304319	OTHER CANNABIS DEPENDENCE CONTINUOUS
30432	CANNABIS DEPENDENCE, EPISODIC USE
304320	MARIJUANA DEPENDENCE EPISODIC

ICD-9 code	Description
304329	OTHER CANNABIS DEPENDENCE EPISODIC
30433	CANNABIS DEPENDENCE, IN REMISSION
304330	MARIJUANA DEPENDENCE IN REMISSION
304339	OTHER CANNABIS DEPENDENCE IN REMISSION
30439	OTHER CANNABIS DEPENDENCE, NOT ELSEWHERE CLASSIFIED
3044	AMPHETAMINE AND OTHER PSYCHOSTIMULANT DEPENDENCE - DO NOT USE
30440	AMPHETAMINE AND OTHER PSYCHOSTIMULANT DEPENDENCE UNSPECIFIED
304400	AMPHETAMINE DEPENDENCE UNSPECIFIED
304401	PRELUDIN DEPENDENCE UNSPECIFIED
304409	OTHER PSYCHOSTIMULANT DEPENDENCE UNSPECIFIED
30441	AMPHETAMINE AND OTHER PSYCHOSTIMULANT DEPENDENCE CONTINUOUS
304410	AMPHETAMINE DEPENDENCE CONTINUOUS
304411	PRELUDIN DEPENDENCE CONTINUOUS
304419	OTHER PSYCHOSTIMULANT DEPENDENCE CONTINUOUS
30442	AMPHETAMINE AND OTHER PSYCHOSTIMULANT DEPENDENCE, EPISODIC USE
304420	AMPHETAMINE DEPENDENCE EPISODIC
304421	PRELUDIN DEPENDENCE EPISODIC
304429	OTHER PSYCHOSTIMULANT DEPENDENCE EPISODIC
30443	AMPHETAMINE AND OTHER PSYCHOSTIMULANT DEPENDENCE, IN REMISSION
304430	AMPHETAMINE DEPENDENCE IN REMISSION
304431	PRELUDIN DEPENDENCE IN REMISSION
304439	OTHER PSYCHOSTIMULANT DEPENDENCE IN REMISSION
30449	OTHER PSYCHOSTIMULANT DEPENDENCE, NOT ELSEWHERE CLASSIFIED
3045	HALLUCINOGEN DEPENDENCE - DO NOT USE
30450	HALLUCINOGEN DEPENDENCE UNSPECIFIED
304500	LSD DEPENDENCE UNSPECIFIED
304509	OTHER HALLUCINOGEN DEPENDENCE UNSPECIFIED
30451	HALLUCINOGEN DEPENDENCE, CONTINUOUS USE
304510	LSD DEPENDENCE CONTINUOUS
304519	OTHER HALLUCINOGEN DEPENDENCE CONTINUOUS
30452	HALLUCINOGEN DEPENDENCE, EPISODIC USE
304520	LSD DEPENDENCE EPISODIC
304529	OTHER HALLUCINOGEN DEPENDENCE EPISODIC
30453	HALLUCINOGEN DEPENDENCE, IN REMISSION

Substance Abuse

ICD-9 code	Description
304530	LSD DEPENDENCE IN REMISSION
304539	OTHER HALLUCINOGEN DEPENDENCE IN REMISSION
30459	OTHER HALLUCINOGEN DEPENDENCE, NOT ELSEWHERE CLASSIFIED
3046	OTHER SPECIFIED DRUG DEPENDENCE - DO NOT USE
30460	OTHER SPECIFIED DRUG DEPENDENCE, UNSPECIFIED USE
304600	PHENCYCLIDINE (PCP) DEPENDENCE UNSPECIFIED
304609	OTHER SPECIFIED DRUG DEPENDENCE UNSPECIFIED
30461	OTHER SPECIFIED DRUG DEPENDENCE, CONTINUOUS USE
304610	PHENCYCLIDINE (PCP) DEPENDENCE CONTINUOUS
304619	OTHER SPECIFIED DRUG DEPENDENCE CONTINUOUS
30462	OTHER SPECIFIED DRUG DEPENDENCE, EPISODIC USE
304620	PHENCYCLIDINE (PCP) DEPENDENCE EPISODIC
304629	OTHER SPECIFIED DRUG DEPENDENCE EPISODIC
30463	OTHER SPECIFIED DRUG DEPENDENCE, IN REMISSION
304630	PHENCYCLIDINE (PCP) DEPENDENCE IN REMISSION
304639	OTHER SPECIFIED DRUG DEPENDENCE IN REMISSION
3047	COMBINATIONS OF OPIOID TYPE DRUG WITH ANY OTHER - DO NOT USE
30470	COMBINATIONS OF OPIOID TYPE DRUG WITH ANY OTHER DRUG DEPENDENCE, UNSP
30471	COMBINATIONS OF OPIOID TYPE DRUG WITH ANY OTHER DRUG DEPENDENCE, CONT
30472	COMBINATIONS OF OPIOID TYPE DRUG WITH ANY OTHER DRUG DEPENDENCE, EPIS
30473	COMBINATIONS OF OPIOID TYPE DRUG WITH ANY OTHER DRUG DEPENDENCE, IN R
3048	COMBINATIONS OF DRUG DEPENDENCE EXCLUDING OPIOID TYPE DRUG -DO NOT
30480	COMBINATIONS OF DRUG DEPENDENCE EXCLUDING OPIOID TYPE DRUG, UNSPECIFI
30481	COMBINATIONS OF DRUG DEPENDENCE EXCLUDING OPIOID TYPE DRUG, CONTINUOU
30482	COMBINATIONS OF DRUG DEPENDENCE EXCLUDING OPIOID TYPE DRUG, EPISODIC
30483	COMBINATIONS OF DRUG DEPENDENCE EXCLUDING OPIOID TYPE DRUG, IN REMISS
3049	UNSPECIFIED DRUG DEPENDENCE - DO NOT USE
30490	UNSPECIFIED DRUG DEPENDENCE NEC, UNSPECIFIED
304900	PHENCYCLIDINE (PCP) DEPENDENCE UNSPECIFIED
304909	UNSPECIFIED DRUG DEPENDENCE NEC UNSPECIFIED
30491	UNSPECIFIED DRUG DEPENDENCE, CONTINUOUS
304910	PHENCYCLIDINE (PCP) DEPENDENCE CONTINUOUS
304919	UNSPECIFIED DRUG DEPENDENCE NEC CONTINUOUS
30492	UNSPECIFIED DRUG DEPENDENCE, EPISODIC USE

ICD-9 code	Description
304920	PHENCYCLIDINE (PCP) DEPENDENCE EPISODIC
304929	UNSPECIFIED DRUG DEPENDENCE NEC EPISODIC
30493	UNSPECIFIED DRUG DEPENDENCE, IN REMISSION
304930	PHENCYCLIDINE (PCP) DEPENDENCE IN REMISSION
304939	UNSPECIFIED DRUG DEPENDENCE NEC IN REMISSION
30499	UNSPECIFIED DRUG DEPENDENCE, NOT ELSEWHERE CLASSIFIED
305	NONDEPENDENT DRUG ABUSE*
3050	ALCOHOL ABUSE*
30500	ALCOHOL ABUSE, UNSPECIFIED DRINKING BEHAVIOR
30501	ALCOHOL ABUSE, CONTINUOUS DRINKING BEHAVIOR
30502	ALCOHOL ABUSE, EPISODIC DRINKING BEHAVIOR
30503	ALCOHOL ABUSE, IN REMISSION
3051	TOBACCO USE DISORDER, UNSPECIFIED USE
30510	TOBACCO USE DISORDER UNSPECIFIED
30511	TOBACCO USE DISORDER CONTINUOUS
30512	TOBACCO USE DISORDER EPISODIC
30513	TOBACCO USE DISORDER IN REMISSION
3052	CANNABIS ABUSE - DO NOT USE
30520	CANNABIS ABUSE UNSPECIFIED
305200	MARIJUANA ABUSE UNSPECIFIED
305209	OTHER CANNABIS ABUSE UNSPECIFIED
30521	CANNABIS ABUSE, CONTINUOUS USE
305210	MARIJUANA ABUSE CONTINUOUS
305219	OTHER CANNABIS ABUSE CONTINUOUS
30522	CANNABIS ABUSE, EPISODIC USE
305220	MARIJUANA ABUSE EPISODIC
305229	OTHER CANNABIS ABUSE EPISODIC
30523	CANNABIS ABUSE, IN REMISSION
305230	MARIJUANA ABUSE IN REMISSION
305239	OTHER CANNABIS ABUSE IN REMISSION
30529	OTHER CANNABIS ABUSE, NOT ELSEWHERE CLASSIFIED
3053	HALLUCINOGEN ABUSE - DO NOT USE
30530	HALLUCINOGEN ABUSE UNSPECIFIED
305300	LSD ABUSE UNSPECIFIED

Substance Abuse

ICD-9 code	Description
305309	OTHER HALLUCINOGEN ABUSE UNSPECIFIED
30531	HALLUCINOGEN ABUSE, CONTINUOUS USE
305310	LSD ABUSE CONTINUOUS
305319	OTHER HALLUCINOGEN ABUSE CONTINUOUS
30532	HALLUCINOGEN ABUSE, EPISODIC USE
305320	LSD ABUSE EPISODIC
305329	OTHER HALLUCINOGEN ABUSE EPISODIC
30533	HALLUCINOGEN ABUSE, IN REMISSION
305330	LSD ABUSE IN REMISSION
305339	OTHER HALLUCINOGEN ABUSE IN REMISSION
30539	OTHER HALLUCINOGEN ABUSE, NOT ELSEWHERE CLASSIFIED
3054	BARBITURATE AND SIMILAR ACTING SEDATIVE OF HYPNOTIC ABUSE -DO NOT
30540	BARBITURATE AND SIMILARLY ACTING SEDATIVE OR HYPNOTIC ABUSE UNSPECIFI
305400	CHLORAL HYDRATE ABUSE UNSPECIFIED
305401	LIBRIUM ABUSE UNSPECIFIED
305402	MEPROBAMATE ABUSE UNSPECIFIED
305403	NOLUDAR METHYPRYLOME ABUSE UNSPECIFIED
305404	PARALDEHYDE ABUSE UNSPECIFIED
305405	PLACIDYL ETHCHLORUYNOL ABUSE UNSPECIFIED
305406	VALIUM DIAZEPAM ABUSE UNSPECIFIED
305407	DORIDEN GLUTETHIMIDE ABUSE UNSPECIFIED
305408	BARBITURATES ABUSE UNSPECIFIED
305409	OTHER SEDATIVE OR HYPNOTIC ABUSE UNSPECIFIED
30541	BARBITURATE AND SIMILARLY ACTING SEDATIVE OR HYPNOTIC ABUSE CONTINUOU
305410	CHLORAL HYDRATE ABUSE CONTINUOUS
305411	LIBRIUM ABUSE CONTINUOUS
305412	MEPROBAMATE ABUSE CONTINUOUS
305413	NOLUDAR METHYPRYLOME ABUSE CONTINUOUS
305414	PARALDEHYDE ABUSE CONTINUOUS
305415	PLACIDYL ETHCHLORUYNOL ABUSE CONTINUOUS
305416	VALIUM DIAZEPAM ABUSE CONTINUOUS
305417	DORIDEN GLUTETHIMIDE ABUSE CONTINUOUS
305418	BARBITURATES ABUSE CONTINUOUS
305419	OTHER SEDATIVE OR HYPNOTIC ABUSE CONTINUOUS

ICD-9 code	Description
30542	BARBITURATE AND SIMILARLY ACTING SEDATIVE OR HYPNOTIC ABUSE EPISODIC
305420	CHLORAL HYDRATE ABUSE EPISODIC
305421	LIBRIUM ABUSE EPISODIC
305422	MEPROBAMATE ABUSE EPISODIC
305423	NOLUDAR METHYPRYLOME ABUSE EPISODIC
305424	PARALDEHYDE ABUSE EPISODIC
305425	PLACIDYL ETHCHLORUYNOL ABUSE EPISODIC
305426	VALIUM DIAZEPAM ABUSE EPISODIC
305427	DORIDEN GLUTETHIMIDE ABUSE EPISODIC
305428	BARBITURATES ABUSE EPISODIC
305429	OTHER SEDATIVE OR HYPNOTIC ABUSE EPISODIC
30543	BARBITURATE AND SIMILARLY ACTING SEDATIVE OR HYPNOTIC ABUSE IN REMISS
305430	CHLORAL HYDRATE ABUSE IN REMISSION
305431	LIBRIUM ABUSE IN REMISSION
305432	MEPROBAMATE ABUSE IN REMISSION
305433	NOLUDAR METHYPRYLOME ABUSE IN REMISSION
305434	PARALDEHYDE ABUSE IN REMISSION
305435	PLACIDYL ETHCHLORUYNOL ABUSE IN REMISSION
305436	VALIUM DIAZEPAM ABUSE IN REMISSION
305437	DORIDEN GLUTETHIMIDE ABUSE IN REMISSION
305438	BARBITURATES ABUSE IN REMISSION
305439	OTHER SEDATIVE OR HYPNOTIC ABUSE IN REMISSION
30544	PARALDEHYDE ABUSE
30545	PLACIDYL,ETHCHLORUYNOL ABUSE
30546	VALIUM, DIAZEPAM ABUSE
30547	DORIDEN, GLUTETHIMIDE ABUSE
30548	BARBITURATES ABUSE
30549	OTHER SEDATIVE OR HYPNOTIC ABUSE, NOT ELSEWHERE CLASSIFIED
3055	OPIOD ABUSE - DO NOT USE
30550	OPIOID ABUSE UNSPECIFIED
305500	HEROIN ABUSE UNSPECIFIED
305501	METHADONE ABUSE UNSPECIFIED
305502	MORPHINE ABUSE UNSPECIFIED
305503	OPIUM ABUSE UNSPECIFIED

Substance Abuse

ICD-9 code	Description
305509	OTHER OPIOD ABUSE NEC UNSPECIFIED
30551	OPIOID ABUSE CONTINUOUS
305510	HEROIN ABUSE CONTINUOUS
305511	METHADONE ABUSE CONTINUOUS
305512	MORPHINE ABUSE CONTINUOUS
305513	OPIUM ABUSE CONTINUOUS
305519	OTHER OPIOD ABUSE NEC CONTINUOUS
30552	OPIOID ABUSE EPISODIC
305520	HEROIN ABUSE EPISODIC
305521	METHADONE ABUSE EPISODIC
305522	MORPHINE ABUSE EPISODIC
305523	OPIUM ABUSE EPISODIC
305529	OTHER OPIOD ABUSE NEC EPISODIC
30553	OPIOID ABUSE IN REMISSION
305530	HEROIN ABUSE IN REMISSION
305531	METHADONE ABUSE IN REMISSION
305532	MORPHINE ABUSE IN REMISSION
305533	OPIUM ABUSE IN REMISSION
305539	OTHER OPIOD ABUSE NEC IN REMISSION
30559	OTHER OPIOID ABUSE, NOT ELSEWHERE CLASSIFIED
3056	COCAINE ABUSE - DO NOT USE
30560	COCAINE ABUSE UNSPECIFIED
30561	COCAINE ABUSE, CONTINUOUS USE
30562	COCAINE ABUSE, EPISODIC USE
30563	COCAINE ABUSE, IN REMISSION
3057	AMPHETAMINE OR RELATED ACTING SYMPATHOMIMETIC ABUSE - DO NOT USE
30570	AMPHETAMINE OR RELATED ACTING SYMPATHOMIMETIC ABUSE UNSPECIFIED
305700	AMPHETAMINE ABUSE UNSPECIFIED
305701	PRELUDIN ABUSE UNSPECIFIED
305709	OTHER RELATED ACTING SYMPATHOMIMETIC ABUSE NEC UNSPECIFIED
30571	AMPHETAMINE OR RELATED ACTING SYMPATHOMIMETIC ABUSE CONTINUOUS
305710	AMPHETAMINE ABUSE CONTINUOUS
305711	PRELUDIN ABUSE CONTINUOUS
305719	OTHER RELATED ACTING SYMPATHOMIMETIC ABUSE NEC CONTINUOUS

ICD-9 code	Description
30572	AMPHETAMINE OR RELATED ACTING SYMPATHOMIMETIC ABUSE EPISODIC
305720	AMPHETAMINE ABUSE EPISODIC
305721	PRELUDIN ABUSE EPISODIC
305729	OTHER RELATED ACTING SYMPATHOMIMETIC ABUSE NEC EPISODIC
30573	AMPHETAMINE OR RELATED ACTING SYMPATHOMIMETIC ABUSE, IN REMISSION
305730	AMPHETAMINE ABUSE IN REMISSION
305731	PRELUDIN ABUSE IN REMISSION
305739	OTHER RELATED ACTING SYMPATHOMIMETIC ABUSE NED IN REMISSION
30579	OTHER RELATED ACTING SYMPATHOMIMETIC ABUSE, NOT ELSEWHERE CLASSIF
3058	ANTIDEPRESSANT TYPE ABUSE - DO NOT USE
30580	ANTIDEPRESSANT TYPE ABUSE, UNSPECIFIED USE
30581	ANTIDEPRESSANT TYPE ABUSE, CONTINUOUS USE
30582	ANTIDEPRESSANT TYPE ABUSE, EPISODIC USE
30583	ANTIDEPRESSANT TYPE ABUSE, IN REMISSION
3059	OTHER MIXED OR UNSPECIFIED DRUG ABUSE - DO NOT USE
30590	OTHER, MIXED, OR UNSPECIFIED RUG ABUSE, UNSPECIFIED USE
305900	PHENCYCLIDINE (PCP) ABUSE (INCLUDES CAFFEINE) UNSPECIFIED
305909	OTHER MIXED/UNSPEC DRUG ABUSE NEC (INCL CAFFEINE) UNSPECIFIED
30591	OTHER, MIXED, OR UNSPECIFIED DRUG ABSE, CONTINUOUS USE
305910	PHENCYCLIDINE (PCP) ABUSE (INCLUDES CAFFEINE) CONTINUOUS
305919	OTHER MIXED/UNSPEC DRUG ABUSE NEC (INCL CAFFEINE) CONTINUOUS
30592	OTHER MIXED, OR UNSPECIFIED DRUG ABUSE, EPISODIC USE
305920	PHENCYCLIDINE (PCP) ABUSE (INCLUDES CAFFEINE) EPISODIC
305929	OTHER MIXED/UNSPEC DRUG ABUSE NEC (INCL CAFFEINE) EPISODIC
30593	OTHER, MIXED, OR UNSPECIFIED DRUG ABUSE, IN REMISSION
305930	PHENCYCLIDINE (PCP) ABUSE (INCLUDES CAFFEINE) IN REMISSION
305939	OTHER MIXED/UNSPEC DRUG ABUSE NEC (INCL CAFFEINE) IN REMISSION
30599	OTHER, MIXED, OR UNSPECIFIED DRUG ABUSE, NOT ELSEWHERE CLASSIFIED

Highlights

Table 12.1

National Overview

In FY-2000, the VHA had 446,525 patients with either a primary or secondary diagnostic code of one or more of the Substance Abuse codes listed above. This number represents approximately thirteen percent (13.47%) of the total patient population during the fiscal year (Table 12.1). As with most patients seen in the VHA, the majority of patients were male (96.45%), with only 3.55% female.

Over one-third of the Substance Abuse patients were between the ages of 45 and 54 (38.55%). The rest of the age groups are distributed as follows: 21.85% under the age of 45, 19.43% between the ages of 55 and 64, 14.86% between the ages of 65 and 74, and 5.3% 75 years of age or older.

The proportion of Substance Abuse patients who were married is below the general patient population in the VHA. Only about thirty-six percent (36.43%) were in this marital category. The “Means Test” categories show that 31.97% were Priority 1 - 3 (service-connected injured) veterans and 56.76% were Priority 5 (low income).

VISN Overview

The volume of patients with Substance Abuse ranged from a high of 44,274 individuals in South Central network (VISN 16) to a low of 8,912 in the Central Plain network (VISN 14). Networks with a relatively high percentage of their patient population in this disease cohort included: the Northwest (VISN 20), Veterans in Partnership (VISN 11) and the Great Lakes (VISN 12). Patients who were married ranges from a low of 25.61% in the New York/New Jersey network (VISN 3) to a high of 42.99% in the South Central network

(VISN 16). The percentage of the total number of Substance Abuse patients who are in the low income categories ranges from a low of 51.02% in the Mid-Atlantic network (VISN 6) to a high of 64.02% in the Desert Pacific network (VISN 22).

Table 12.2

This table compares utilization by the Substance Abuse **primary** diagnosis group for all conditions with utilization by all VA patients for all conditions. Note that for this table, only patients who had a primary diagnosis of Substance Abuse were selected. If a patient had Substance Abuse as a secondary diagnosis only, he/she is not included. Further, for our primary diagnosis Substance Abuse group we examined all utilization that occurred during the fiscal year, both Substance Abuse-specific and all other non-Substance Abuse related medical care obtained.

As an example of what the data show and how to interpret the findings, examine the Capital network (VISN 5). In this particular network, 9.6% of the total patients seen at a VA facility in fiscal year 2000 had a primary diagnosis of Substance Abuse. This group of patients accounted for 22.34% of the total bed-days of care in VISN 5, 28.46% of total discharges in VISN 5, and 27.51% of outpatient visits in VISN 5 made by all patients of VA health care services in the network for all medical conditions.

Table 12.3

Table 12.3 is similar to Table 12.2 except that patients who only had a **secondary** diagnosis of Substance Abuse are examined rather than patients who had a primary diagnosis. This table compares utilization by the Substance Abuse secondary diagnosis group for all health conditions they had during the year (i.e., includes both Substance Abuse-specific utilization and utilization for all other non-Substance Abuse care the patient may have received) with utilization by all VISN patients for all conditions.

Using the example of VISN 5, the data can be interpreted as follows: 4.17% of the patients in VISN 5 had at most a secondary diagnosis of Substance Abuse, but never a primary diagnosis. This group of patients accounted for 10.47% of the total bed-days of care, 11.06% of total discharges and 5.17% of outpatient visits utilized by all patients in the network for all conditions.

Table 12.4

Table 12.4 compares resource utilization specifically directed at treating Substance Abuse. In other words, we examine the utilization for which the primary diagnosis (DXLSF) was a defining diagnosis for the Substance Abuse, with utilization for all conditions by all patients in each network.

For example, in VISN 5, 9.6% of the patients had some utilization for which the primary diagnosis was Substance Abuse. Utilization specifically directed at treating the Substance Abuse accounted for 8.94% of all bed-days of care, 12.6% of all discharges, and 13.37% of all outpatient visits.

Table 12.5

Table 12.5 combines the information from Tables 12.2 and 12.4, comparing utilization by the Substance Abuse primary diagnosis group specifically directed at treating their condition with utilization by this same group for all conditions. For example, in VISN 5, 9.6% (N=8,464) of the patients had some utilization for Substance Abuse. These patients accounted for 49,678 bed-days of care in FY-2000, of which 19,884 or about 40%, were utilized specifically for treating their Substance Abuse (i.e., primary diagnosis (DXLSF) of Substance Abuse). Similarly, approximately 44% of the discharges for patients in the Substance Abuse primary diagnosis group resulted from inpatient stays to treat their disease, and 49% of the outpatient

visits made by these patients were for specifically for the treatment of Substance Abuse.

Costs

Cost data are reported for utilization of VA services by VA patients with Substance Abuse in Table 12.6 and Table 12.7. Veterans with Substance Abuse are identified by a Substance Abuse diagnosis for at least one inpatient or outpatient service received. We separately report for veterans who had at least one primary diagnosis of Substance Abuse and veterans whose only diagnoses of Substance Abuse are secondary to another diagnosis. Costs are for VA utilization and include inpatient, outpatient, and pharmacy services for all causes, not just for Substance Abuse-specific use. That is, we report all VA costs for all causes for individuals identified as having Substance Abuse.

There were 446,499 individuals with at least one primary or secondary diagnosis of Substance Abuse for whom cost data were available, and these costs averaged \$9,489 per veteran. Breaking these costs down by whether or not the veteran had at least one primary diagnosis of Substance Abuse, results in an average cost of \$10,010 per veteran for those with at least one primary care diagnosis of Substance Abuse and \$8,936 per veteran for those patients with only secondary diagnoses.

Focusing on those patients with at least one primary diagnosis of Substance Abuse, the \$10,010 costs per veteran are distributed as follows: 19.96% are for inpatient medical/surgical services, 35.16% are for other inpatient services, 36.62% are for outpatient services, and 8.26% are for pharmaceutical services. Across VISNs, overall costs per veteran with a primary diagnosis of Substance Abuse ranged from a low of \$6,351 (VISN 18) to a high of \$16,130 (VISN 3) per veteran.

Substance Abuse

**Table 12.1:
Overall Prevalence Statistics – Substance Abuse, FY-2000**

Veterans Integrated Service Network	Total Number of Patients	Patients with Substance Abuse		Gender (%)		Age Group (%)					Marital Status (%)		Means Test Status (%)	
		N	(%)	M	F	<45	45-54	55-64	65-74	75+	Married	Not Married	Service Connected	Low Income
New England (1)	158,204	24,149	15.26	96.67	3.33	19.49	39.89	18.93	16.15	5.54	34.05	64.93	37.36	51.62
Upstate NY (2)	100,499	12,720	12.66	96.67	3.33	25.10	36.17	17.30	15.55	5.87	33.81	64.61	29.83	56.58
NY/NJ (3)	166,593	16,214	9.73	97.80	2.20	24.47	40.85	16.58	13.32	4.77	25.61	73.34	30.39	49.67
Stars and Stripes (4)	202,472	20,206	9.98	96.99	3.00	24.93	40.34	16.96	13.15	4.62	31.64	66.87	30.81	56.15
Capitol (5)	88,163	12,144	13.77	96.42	3.58	27.66	41.04	15.09	11.89	4.31	26.50	72.55	29.19	59.08
Mid-Atlantic (6)	161,081	21,817	13.54	94.89	5.11	23.58	39.71	17.79	14.04	4.87	40.20	58.84	38.93	51.02
Atlantic (7)	201,514	26,519	13.16	95.87	4.13	23.37	39.96	18.64	13.90	4.13	40.42	58.12	33.76	55.19
Sunshine (8)	308,906	38,079	12.33	95.77	4.23	20.10	37.62	21.90	15.12	5.27	38.23	57.96	35.26	56.14
Mid-South (9)	165,501	23,898	14.44	96.64	3.36	20.70	38.89	20.01	15.16	5.25	42.65	56.64	32.55	57.50
Ohio (10)	117,463	17,487	14.89	96.30	3.69	28.91	39.78	15.83	11.28	4.20	29.50	69.77	27.76	61.60
Vets in Partnership (11)	142,393	23,559	16.55	96.96	3.03	22.82	38.70	18.35	15.18	4.95	33.99	65.36	27.58	60.97
Great Lakes (12)	142,079	22,907	16.12	96.57	3.43	24.14	36.98	17.55	15.02	6.31	31.65	67.37	27.00	59.06
Upper Midwest (13)	96,279	14,368	14.92	96.91	3.09	20.15	35.36	18.99	18.67	6.83	38.53	59.86	31.65	51.33
Central Plains (14)	73,699	8,912	12.09	96.69	3.31	21.88	34.95	19.37	18.16	5.64	37.38	61.84	29.13	58.65
Heartland (15)	148,229	23,400	15.79	97.03	2.97	21.54	37.99	19.78	15.58	5.11	39.50	59.88	28.43	60.51
South Central (16)	294,286	44,274	15.04	96.53	3.47	20.02	39.02	20.90	14.77	5.28	42.99	55.09	34.32	57.04
Heart of Texas (17)	151,601	17,064	11.26	95.33	4.67	23.43	40.34	18.89	12.92	4.42	36.84	62.44	35.19	53.14
Southwest (18)	154,764	24,517	15.84	96.19	3.80	18.94	34.69	21.45	17.47	7.44	41.83	57.16	33.06	55.80
Rocky Mt. (19)	95,866	13,704	14.29	95.98	4.02	21.58	38.81	20.36	14.34	4.91	36.57	62.47	33.28	55.94
Northwest (20)	143,215	24,513	17.12	96.08	3.92	22.87	40.40	18.77	13.10	4.86	32.95	66.04	36.89	51.49
Sierra Pacific (21)	149,020	21,645	14.52	96.43	3.57	20.24	42.49	19.03	12.86	5.36	29.54	69.42	33.71	56.85
Desert Pacific (22)	178,204	26,390	14.81	96.44	3.56	22.99	38.77	22.15	12.14	3.94	26.04	72.74	27.28	64.02
National	3,314,672	446,525	13.47	96.45	3.55	21.85	38.55	19.43	14.86	5.30	36.43	62.26	31.97	56.76

**Table 12.2:
Overall Resource Utilization – Substance Abuse (Primary Diagnosis Group) Compared to All Users, FY-2000**

Veterans Integrated Service Network (VISN)	Total Patients		Total Patients Substance Abuse			Bed Days of Care			Discharges			Outpatient Visits		
						Total	Substance Abuse		Total	Substance Abuse		Total	Substance Abuse	
	N		N	%		N	N	%	N	N	%	N	N	%
New England (1)	158,204		13,251	8.38		303,134	58,511	19.30	24,413	6,821	27.94	1,990,550	429,255	21.56
Upstate NY (2)	100,499		6,993	6.96		120,203	21,332	17.75	11,871	2,542	21.41	1,093,796	206,411	18.87
NY/NJ (3)	166,593		10,907	6.55		405,186	80,128	19.78	24,128	5,819	24.12	1,854,064	408,229	22.02
Stars and Stripes (4)	202,472		12,476	6.16		284,688	49,713	17.46	24,122	5,290	21.93	1,846,937	329,996	17.87
Capitol (5)	88,163		8,464	9.60		222,405	49,678	22.34	17,107	4,868	28.46	1,007,572	277,168	27.51
Mid-Atlantic (6)	161,081		10,408	6.46		361,832	59,533	16.45	31,256	6,853	21.93	1,491,680	197,991	13.27
Atlantic (7)	201,514		13,461	6.68		369,514	53,973	14.61	29,275	5,082	17.36	1,891,761	286,927	15.17
Sunshine (8)	308,906		19,555	6.33		392,501	54,955	14.00	41,850	7,443	17.78	3,109,217	381,106	12.26
Mid-South (9)	165,501		10,690	6.46		316,108	44,025	13.93	34,579	6,027	17.43	1,483,519	177,292	11.95
Ohio (10)	117,463		11,140	9.48		191,574	41,576	21.70	18,945	4,918	25.96	1,327,847	330,887	24.92
Vets in Partnership (11)	142,393		11,898	8.36		311,786	50,335	16.14	23,779	5,556	23.37	1,368,643	259,770	18.98
Great Lakes (12)	142,079		12,669	8.92		334,130	66,403	19.87	30,157	7,156	23.73	1,715,017	447,770	26.11
Upper Midwest (13)	96,279		8,161	8.48		107,644	18,284	16.99	16,092	3,123	19.41	934,533	204,687	21.90
Central Plains (14)	73,699		3,735	5.07		76,697	14,937	19.48	9,898	1,587	16.03	674,604	83,430	12.37
Heartland (15)	148,229		10,371	7.00		211,861	45,546	21.50	25,568	5,623	21.99	1,458,394	225,240	15.44
South Central (16)	294,286		19,697	6.69		454,315	67,288	14.81	47,751	7,662	16.05	2,750,358	428,648	15.59
Heart of Texas (17)	151,601		9,447	6.23		297,463	46,815	15.74	25,932	5,103	19.68	1,544,273	254,885	16.51
Southwest (18)	154,764		10,852	7.01		167,362	32,791	19.59	23,822	4,831	20.28	1,574,259	185,680	11.79
Rocky Mt. (19)	95,866		7,400	7.72		132,102	25,629	19.40	15,065	2,679	17.78	959,415	141,085	14.71
Northwest (20)	143,215		12,797	8.94		181,076	42,922	23.70	24,296	5,792	23.84	1,488,150	291,126	19.56
Sierra Pacific (21)	149,020		11,007	7.39		214,370	58,200	27.15	19,163	4,397	22.95	1,630,530	302,884	18.58
Desert Pacific (22)	178,204		15,236	8.55		231,584	38,162	16.48	25,132	4,915	19.56	2,119,773	412,729	19.47
National	3,314,672		230,526	6.95		5,687,535	1,020,736	17.95	544,201	114,087	20.96	35,314,892	6,263,196	17.74

Substance Abuse

**Table 12.3:
Overall Resource Utilization – Substance Abuse (Secondary Diagnosis Group) Compared to All Users, FY-2000**

Veterans Integrated Service Network (VISN)	Total Patients		Total Patients Substance Abuse			Bed Days of Care			Discharges			Outpatient Visits		
	N	N	%	Total	Substance Abuse		Total	Substance Abuse		Total	Substance Abuse			
				N	N	%	N	N	%	N	N	%		
New England (1)	158,204	10,898	6.89	303,134	44,493	14.68	24,413	3,399	13.92	1,990,550	180,945	9.09		
Upstate NY (2)	100,499	5,727	5.70	120,203	23,783	19.79	11,871	2,202	18.55	1,093,796	90,968	8.32		
NY/NJ (3)	166,593	5,307	3.19	405,186	42,113	10.39	24,128	2,112	8.75	1,854,064	82,762	4.46		
Stars and Stripes (4)	202,472	7,730	3.82	284,688	38,684	13.59	24,122	3,044	12.62	1,846,937	102,129	5.53		
Capitol (5)	88,163	3,680	4.17	222,405	23,277	10.47	17,107	1,892	11.06	1,007,572	52,061	5.17		
Mid-Atlantic (6)	161,081	11,409	7.08	361,832	44,576	12.32	31,256	4,409	14.11	1,491,680	130,942	8.78		
Atlantic (7)	201,514	13,058	6.48	369,514	50,573	13.69	29,275	4,901	16.74	1,891,761	150,235	7.94		
Sunshine (8)	308,906	18,524	6.00	392,501	65,245	16.62	41,850	7,610	18.18	3,109,217	243,341	7.83		
Mid-South (9)	165,501	13,208	7.98	316,108	52,949	16.75	34,579	5,951	17.21	1,483,519	145,832	9.83		
Ohio (10)	117,463	6,347	5.40	191,574	36,720	19.17	18,945	3,378	17.83	1,327,847	97,981	7.38		
Vets in Partnership (11)	142,393	11,661	8.19	311,786	54,455	17.47	23,779	4,672	19.65	1,368,643	153,078	11.18		
Great Lakes (12)	142,079	10,238	7.21	334,130	38,152	11.42	30,157	3,808	12.63	1,715,017	149,423	8.71		
Upper Midwest (13)	96,279	6,207	6.45	107,644	18,473	17.16	16,092	2,533	15.74	934,533	78,011	8.35		
Central Plains (14)	73,699	5,177	7.02	76,697	13,013	16.97	9,898	1,771	17.89	674,604	64,172	9.51		
Heartland (15)	148,229	13,029	8.79	211,861	42,068	19.86	25,568	4,624	18.09	1,458,394	158,519	10.87		
South Central (16)	294,286	24,577	8.35	454,315	105,888	23.31	47,751	11,133	23.31	2,750,358	284,361	10.34		
Heart of Texas (17)	151,601	7,617	5.02	297,463	35,558	11.95	25,932	3,316	12.79	1,544,273	90,722	5.87		
Southwest (18)	154,764	13,665	8.83	167,362	31,928	19.08	23,822	4,815	20.21	1,574,259	171,621	10.90		
Rocky Mt. (19)	95,866	6,304	6.58	132,102	21,317	16.14	15,065	2,345	15.57	959,415	77,795	8.11		
Northwest (20)	143,215	11,716	8.18	181,076	35,802	19.77	24,296	4,439	18.27	1,488,150	155,698	10.46		
Sierra Pacific (21)	149,020	10,638	7.14	214,370	40,698	18.98	19,163	3,652	19.06	1,630,530	153,375	9.41		
Desert Pacific (22)	178,204	11,154	6.26	231,584	41,921	18.10	25,132	4,522	17.99	2,119,773	163,123	7.70		
National	3,314,672	215,999	6.52	5,687,535	901,686	15.85	544,201	90,528	16.64	35,314,892	2,977,094	8.43		

**Table 12.4:
Resource Utilization for Treatment of Substance Abuse (Primary Diagnosis Group) Compared to Overall Resource Utilization
by All Users, FY-2000**

Veterans Integrated Service Network (VISN)	Total Patients		Total Patients Substance Abuse			Bed Days of Care			Discharges			Outpatient Visits		
	N		N		%	Total		Substance Abuse		%	Total		Substance Abuse	
	N		N	%	N	N	%	N	N	%	N	N	%	
New England (1)	158,204		13,251	8.38	303,134	24,303	8.02	24,413	3,633	14.88	1,990,550	147,368	7.40	
Upstate NY (2)	100,499		6,993	6.96	120,203	8,244	6.86	11,871	1,073	9.04	1,093,796	64,061	5.86	
NY/NJ (3)	166,593		10,907	6.55	405,186	30,416	7.51	24,128	2,723	11.29	1,854,064	200,820	10.83	
Stars and Stripes (4)	202,472		12,476	6.16	284,688	18,690	6.57	24,122	2,124	8.81	1,846,937	161,416	8.74	
Capitol (5)	88,163		8,464	9.60	222,405	19,884	8.94	17,107	2,155	12.60	1,007,572	134,662	13.37	
Mid-Atlantic (6)	161,081		10,408	6.46	361,832	26,173	7.23	31,256	3,147	10.07	1,491,680	69,953	4.69	
Atlantic (7)	201,514		13,461	6.68	369,514	17,664	4.78	29,275	1,540	5.26	1,891,761	119,412	6.31	
Sunshine (8)	308,906		19,555	6.33	392,501	16,181	4.12	41,850	2,329	5.57	3,109,217	115,298	3.71	
Mid-South (9)	165,501		10,690	6.46	316,108	16,356	5.17	34,579	2,659	7.69	1,483,519	57,582	3.88	
Ohio (10)	117,463		11,140	9.48	191,574	17,032	8.89	18,945	2,240	11.82	1,327,847	169,273	12.75	
Vets in Partnership (11)	142,393		11,898	8.36	311,786	19,243	6.17	23,779	2,319	9.75	1,368,643	110,715	8.09	
Great Lakes (12)	142,079		12,669	8.92	334,130	28,028	8.39	30,157	3,102	10.29	1,715,017	235,720	13.74	
Upper Midwest (13)	96,279		8,161	8.48	107,644	5,512	5.12	16,092	1,238	7.69	934,533	98,618	10.55	
Central Plains (14)	73,699		3,735	5.07	76,697	5,800	7.56	9,898	548	5.54	674,604	31,169	4.62	
Heartland (15)	148,229		10,371	7.00	211,861	15,178	7.16	25,568	2,337	9.14	1,458,394	55,230	3.79	
South Central (16)	294,286		19,697	6.69	454,315	15,012	3.30	47,751	2,470	5.17	2,750,358	186,395	6.78	
Heart of Texas (17)	151,601		9,447	6.23	297,463	16,470	5.54	25,932	2,074	8.00	1,544,273	83,335	5.40	
Southwest (18)	154,764		10,852	7.01	167,362	13,989	8.36	23,822	1,864	7.82	1,574,259	54,039	3.43	
Rocky Mt. (19)	95,866		7,400	7.72	132,102	4,858	3.68	15,065	638	4.23	959,415	43,957	4.58	
Northwest (20)	143,215		12,797	8.94	181,076	18,460	10.19	24,296	2,520	10.37	1,488,150	119,923	8.06	
Sierra Pacific (21)	149,020		11,007	7.39	214,370	28,090	13.10	19,163	2,062	10.76	1,630,530	143,762	8.82	
Desert Pacific (22)	178,204		15,236	8.55	231,584	7,477	3.23	25,132	1,162	4.62	2,119,773	165,971	7.83	
National	3,314,672		230,526	6.95	5,687,535	373,060	6.56	544,201	45,957	8.44	35,314,892	2,568,679	7.27	

**Table 12.5:
Resource Utilization for Treatment of Substance Abuse Compared to Overall Utilization by the Substance Abuse Cohort
(Primary Diagnosis Group), FY-2000**

Veterans Integrated Service Network (VISN)	Total Patients		Total Patients Substance Abuse			Bed Days of Care			Discharges			Outpatient Visits		
	N		N	%		Total	Substance Abuse		Total	Substance Abuse		Total	Substance Abuse	
	N		N	N	%	N	N	%	N	N	%	N	N	%
New England (1)	158,204		13,251	8,38		58,511	24,303	41.54	6,821	3,633	53.26	429,255	147,368	34.33
Upstate NY (2)	100,499		6,993	6.96		21,332	8,244	38.65	2,542	1,073	42.21	206,411	64,061	31.04
NY/NJ (3)	166,593		10,907	6.55		80,128	30,416	37.96	5,819	2,723	46.79	408,229	200,820	49.19
Stars and Stripes (4)	202,472		12,476	6.16		49,713	18,690	37.60	5,290	2,124	40.15	329,996	161,416	48.91
Capitol (5)	88,163		8,464	9.60		49,678	19,884	40.03	4,868	2,155	44.27	277,168	134,662	48.58
Mid-Atlantic (6)	161,081		10,408	6.46		59,533	26,173	43.96	6,853	3,147	45.92	197,991	69,953	35.33
Atlantic (7)	201,514		13,461	6.68		53,973	17,664	32.73	5,082	1,540	30.30	286,927	119,412	41.62
Sunshine (8)	308,906		19,555	6.33		54,955	16,181	29.44	7,443	2,329	31.29	381,106	115,298	30.25
Mid-South (9)	165,501		10,690	6.46		44,025	16,356	37.15	6,027	2,659	44.12	177,292	57,582	32.48
Ohio (10)	117,463		11,140	9.48		41,576	17,032	40.97	4,918	2,240	45.55	330,887	169,273	51.16
Vets in Partnership (11)	142,393		11,898	8.36		50,335	19,243	38.23	5,556	2,319	41.74	259,770	110,715	42.62
Great Lakes (12)	142,079		12,669	8.92		66,403	28,028	42.21	7,156	3,102	43.35	447,770	235,720	52.64
Upper Midwest (13)	96,279		8,161	8.48		18,284	5,512	30.15	3,123	1,238	39.64	204,687	98,618	48.18
Central Plains (14)	73,699		3,735	5.07		14,937	5,800	38.83	1,587	548	34.53	83,430	31,169	37.36
Heartland (15)	148,229		10,371	7.00		45,546	15,178	33.32	5,623	2,337	41.56	225,240	55,230	24.52
South Central (16)	294,286		19,697	6.69		67,288	15,012	22.31	7,662	2,470	32.24	428,648	186,395	43.48
Heart of Texas (17)	151,601		9,447	6.23		46,815	16,470	35.18	5,103	2,074	40.64	254,885	83,335	32.70
Southwest (18)	154,764		10,852	7.01		32,791	13,989	42.66	4,831	1,864	38.58	185,680	54,039	29.10
Rocky Mt. (19)	95,866		7,400	7.72		25,629	4,858	18.96	2,679	638	23.81	141,085	43,957	31.16
Northwest (20)	143,215		12,797	8.94		42,922	18,460	43.01	5,792	2,520	43.51	291,126	119,923	41.19
Sierra Pacific (21)	149,020		11,007	7.39		58,200	28,090	48.26	4,397	2,062	46.90	302,884	143,762	47.46
Desert Pacific (22)	178,204		15,236	8.55		38,162	7,477	19.59	4,915	1,162	23.64	412,729	165,971	40.21
National	3,314,672		230,526	6.95		1,020,736	373,060	36.55	114,087	45,957	40.28	6,263,196	2,568,679	41.01

**Table 12.6:
FY-2000 Cost of Substance Abuse (Primary Diagnosis)**



Veterans Integrated Service Network	No. of Patients	Outpatient		Inpatient Med/Surg		Inpatient Other		Pharmacy		Total
		\$	%	\$	%	\$	%	\$	%	\$
New England (1)	13,273	61,970,601	45.80%	22,520,040	16.65%	40,542,470	29.97%	10,262,032	7.58%	135,295,142
Upstate NY (2)	6,995	27,786,737	39.43%	9,603,623	13.63%	27,437,958	38.94%	5,641,816	8.01%	70,470,134
NY/NJ (3)	10,920	59,713,949	33.90%	25,122,330	14.26%	79,370,289	45.06%	11,936,571	6.78%	176,143,139
Stars and Stripes (4)	12,502	38,394,091	32.51%	22,304,689	18.89%	48,366,271	40.95%	9,038,276	7.65%	118,103,327
Capitol (5)	8,459	31,633,797	33.69%	20,431,377	21.76%	36,820,857	39.21%	5,013,905	5.34%	93,899,936
Mid-Atlantic (6)	10,427	24,535,979	26.53%	20,061,503	21.69%	39,795,280	43.03%	8,099,158	8.76%	92,491,920
Atlantic (7)	13,514	41,367,003	39.05%	23,840,550	22.51%	29,218,806	27.59%	11,495,004	10.85%	105,921,364
Sunshine (8)	19,684	55,494,554	38.32%	31,766,247	21.93%	40,060,925	27.66%	17,509,078	12.09%	144,830,804
Mid-South (9)	10,700	26,389,446	32.53%	21,273,966	26.22%	25,899,855	31.92%	7,568,458	9.33%	81,131,725
Ohio (10)	11,154	44,547,649	40.07%	17,168,792	15.44%	43,721,805	39.32%	5,746,208	5.17%	111,184,453
Vets in Partnership (11)	11,922	39,717,122	40.31%	18,416,259	18.69%	31,448,647	31.92%	8,939,253	9.07%	98,521,281
Great Lakes (12)	12,689	56,253,841	38.55%	23,258,178	15.94%	57,004,034	39.06%	9,407,595	6.45%	145,923,648
Upper Midwest (13)	8,153	29,906,302	40.07%	16,145,250	21.63%	21,027,489	28.17%	7,553,952	10.12%	74,632,993
Central Plains (14)	3,761	12,666,667	33.19%	6,902,074	18.08%	15,301,216	40.09%	3,296,749	8.64%	38,166,705
Heartland (15)	10,408	31,589,712	37.98%	16,969,344	20.40%	27,564,334	33.14%	7,043,138	8.47%	83,166,528
South Central (16)	19,780	59,955,003	37.77%	35,677,815	22.48%	47,672,357	30.03%	15,423,194	9.72%	158,728,370
Heart of Texas (17)	9,460	29,771,491	31.85%	20,170,051	21.58%	36,935,870	39.51%	6,602,236	7.06%	93,479,648
Southwest (18)	10,916	23,303,196	33.61%	20,584,404	29.69%	18,900,896	27.26%	6,538,647	9.43%	69,327,143
Rocky Mt. (19)	7,450	15,930,017	31.68%	14,595,753	29.03%	14,260,922	28.36%	5,497,100	10.93%	50,283,793
Northwest (20)	12,762	38,296,170	32.16%	22,338,580	18.76%	50,211,292	42.16%	8,244,212	6.92%	119,090,254
Sierra Pacific (21)	11,044	40,712,419	36.88%	19,293,585	17.48%	41,054,052	37.19%	9,336,786	8.46%	110,396,841
Desert Pacific (22)	15,289	55,018,376	40.39%	32,159,523	23.61%	38,729,036	28.43%	10,301,618	7.56%	136,208,553
National	230513	844,954,122	36.62%	460,603,934	19.96%	811,344,660	35.16%	190,494,985	8.26%	2,307,397,701

Substance Abuse






**Table 12.7:
FY-2000 Cost of Substance Abuse (Secondary Diagnosis)**

Veterans Integrated Service Network	No. of Patients	Outpatient		Inpatient Med/Surg		Inpatient Other		Pharmacy		Total
		\$	%	\$	%	\$	%	\$	%	\$
New England (1)	10,913	29,274,091	31.83%	31,586,338	34.34%	21,658,143	23.55%	9,454,723	10.28%	91,973,295
Upstate NY (2)	5,747	16,335,520	29.83%	22,777,211	41.59%	9,678,245	17.67%	5,973,134	10.91%	54,764,110
NY/NJ (3)	5,333	15,128,803	22.02%	21,568,673	31.40%	25,337,601	36.88%	6,664,246	9.70%	68,699,323
Stars and Stripes (4)	7,756	15,113,453	21.23%	26,609,019	37.39%	22,499,032	31.61%	6,953,727	9.77%	71,175,232
Capitol (5)	3,686	8,508,237	20.29%	19,392,607	46.24%	11,175,356	26.65%	2,865,094	6.83%	41,941,294
Mid-Atlantic (6)	11,462	21,327,656	25.36%	33,563,572	39.91%	18,581,479	22.09%	10,628,345	12.64%	84,101,052
Atlantic (7)	13,129	25,098,776	26.35%	42,135,359	44.24%	16,659,869	17.49%	11,346,112	11.91%	95,240,116
Sunshine (8)	18,618	40,379,104	27.86%	58,305,931	40.23%	28,102,606	19.39%	18,155,115	12.53%	144,942,756
Mid-South (9)	13,253	25,443,020	24.56%	49,709,924	47.99%	17,005,313	16.42%	11,418,336	11.02%	103,576,593
Ohio (10)	6,377	16,162,633	21.96%	29,472,781	40.04%	21,838,253	29.67%	6,129,608	8.33%	73,603,276
Vets in Partnership (11)	11,712	30,945,791	28.38%	38,274,772	35.11%	28,064,313	25.74%	11,743,023	10.77%	109,027,899
Great Lakes (12)	10,273	26,098,065	30.15%	34,299,370	39.62%	16,687,934	19.28%	9,486,956	10.96%	86,572,324
Upper Midwest (13)	6,218	12,505,880	22.50%	25,440,602	45.77%	11,352,492	20.42%	6,289,006	11.31%	55,587,979
Central Plains (14)	5,201	10,432,823	29.14%	14,591,571	40.76%	5,757,729	16.08%	5,017,701	14.02%	35,799,824
Heartland (15)	13,077	24,196,244	27.81%	35,607,894	40.93%	16,429,013	18.89%	10,758,908	12.37%	86,992,059
South Central (16)	24,673	49,753,079	24.07%	96,340,190	46.62%	37,292,723	18.04%	23,282,566	11.27%	206,668,558
Heart of Texas (17)	7,666	13,024,403	20.14%	30,370,545	46.97%	15,075,205	23.31%	6,192,157	9.58%	64,662,311
Southwest (18)	13,739	25,386,219	29.12%	39,528,594	45.34%	12,660,281	14.52%	9,600,600	11.01%	87,175,694
Rocky Mt. (19)	6,363	10,586,591	22.68%	21,747,407	46.59%	9,374,339	20.08%	4,967,353	10.64%	46,675,691
Northwest (20)	11,695	27,111,578	28.46%	37,795,317	39.67%	20,239,674	21.25%	10,118,784	10.62%	95,265,354
Sierra Pacific (21)	10,690	26,804,547	25.76%	38,577,515	37.08%	28,504,680	27.40%	10,149,886	9.76%	104,036,629
Desert Pacific (22)	11,212	28,409,809	23.48%	56,757,690	46.90%	26,830,784	22.17%	9,007,501	7.44%	121,005,784
National	215926	498,026,321	25.81%	804,452,883	41.69%	420,805,065	21.81%	206,202,882	10.69%	1,929,487,152

Map 12.1



Number of Patients

-  No Patients
-  1 - 100
-  101 - 500
-  501 - 1,000
-  Greater than 1,000

Number of VA Patients with Substance Abuse by County FY-2000

VA Health Care Atlas
HSR&D SDR 01-175



Source: VA Medical SAS Databases, FY-00
Created in ArcGIS 8 using ArcMap

Substance Abuse

Map 12.2



Percent of Patients






**Percent of VA Patients with Substance Abuse
by County FY-2000**

VA Health Care Atlas
HSR&D SDR 01-175

Source: VA Medical SAS Databases, FY-00

Created in ArcGIS 8 using ArcMap

Map 12.3




Percent Disease-Specific Visits of Total Visits (Substance Abuse) by County FY-2000

VA Health Care Atlas
HSR&D SDR 01-175

Source: VA Medical SAS Databases, FY-00
Created in ArcGIS 8 using ArcMap

Substance Abuse

Map 12.4



Percent

- No Discharges
- .1 - 10.0%
- 10.1 - 20.0%
- 20.1 - 30.0%
- Greater than 30.0%



Percent Disease-Specific Discharges of Total Discharges (Substance Abuse) by County FY-2000

VA Health Care Atlas
HSR&D SDR 01-175






Source: VA Medical SAS Databases, FY-00

Created in ArcGIS 8 using ArcMap

Map 12.5



Number

-  No Visits
-  .1 - 12.0
-  12.1 - 24.0
-  24.1 - 36.0
-  Greater than 36.0


Average Number of Visits for Patients with Substance Abuse by County FY-2000

VA Health Care Atlas
HSR&D SDR 01-175



Source: VA Medical SAS Databases, FY-00
Created in ArcGIS 8 using ArcMap

Substance Abuse

Map 12.6



Number per 1,000



Disease Specific Discharges per 1,000 Patients with Substance Abuse by County FY-2000

VA Health Care Atlas
HSR&D SDR 01-175

Source: VA Medical SAS Databases, FY-00
Created in ArcGIS 8 using ArcMap

For More Information

The economic cost of substance abuse involving alcohol and drugs in the United States is estimated to be more than \$150 billion per year, in addition to more than \$50 billion from tobacco use. Substance use disorders also are prevalent and extremely costly among VA patients. The high prevalence and cost of substance use disorders, coupled with the increasing complexity of veteran patients' disorders, point to the need for improved quality of care in this area. The Quality Enhancement Research Initiative's Substance Abuse Module (QSAM) employs the QUERI process to improve the quality of care and health outcomes of veterans with substance use disorders.

QSAM is located at the HSR&D Center of Excellence in Palo Alto, California and is co-chaired by John Finney, PhD, (Research Coordinator) and Mark Willenbring, MD (Clinical Coordinator). Researchers or other interested parties are encouraged to contact the QSAM Coordinator to learn more about VHA's current research foci and ongoing projects in the area of Substance Abuse:

Janice Byer
Administrative Coordinator
VA Palo Alto Health Care System (152-MPD)
795 Willow Road
Palo Alto, CA 95025

Telephone: 650/493-2000 x22808
Fax: 650/617-2736
E-mail: Janice.Byer@med.va.gov

A summary of QSAM activities is provided below. These descriptions were extracted from the Fact Sheets available on the Web site: <http://www.hsrd.research.va.gov/queri.cfm>.

Research Focus and Translation Activities

Since its inception in 1998, QSAM's agenda has included a cost and outcomes analysis of two pharmacologic treatments for opioid dependence; a review of best practices for patients who are diagnosed with both substance abuse and posttraumatic stress disorder (PTSD); and a project to characterize mental health service episodes and link these to patient outcomes. This agenda broadened in QSAM's second year to include research projects on screening and brief intervention practices for substance abuse in primary care, and on, site versus referral models of primary care for substance abuse patients. More recently funded projects focus on continuity in substance abuse care (best practices, outcomes, and costs); clinical practices and outcomes in VA methadone maintenance programs; and a system for monitoring substance abuse patients' outcomes and care.

Opioid Agonist Effectiveness Initiative (OpiATE)

VA cares for over 25,000 patients who are dependent on opioids. However, the number of veterans with an opioid dependence diagnosis is almost four times greater than the number receiving methadone maintenance. Currently, there are only 33 VA facilities where methadone maintenance is available. QSAM research shows that providing opioid-dependent individuals with methadone maintenance treatment has an incremental cost of \$5,915 per life-year gained. This is a much lower cost effectiveness ratio than that for medical therapy for hypertension, for example, or dialysis for renal failure, which cost \$21,700 and \$38,000, respectively, per life-year gained. Despite this, there are several barriers to increasing methadone maintenance treatment, not the least of which are the misconceptions and stigma attached to treating drug addiction with another drug. Because methadone treatment has been found to be highly cost-effective for opioid addiction, the QSAM Clinical Coordinator, Mark Willenbring, MD, is working with a translation team to enhance access to, and the quality of methadone maintenance treatment within VA. In the quality

improvement component, interventions are being conducted to improve outcomes (reduced proportion of urine screens that are positive for illicit drugs and increased patient retention) by bringing about evidence-based practices with respect to methadone dosing, counseling, maintenance (versus detoxification) orientation, and contingency management techniques.

Recycling Smokers Through Effective Treatment (RESET)

Tobacco consumption is the single most preventable risk factor for disease. Because of the costly morbidity associated with tobacco use, interventions that achieve even small increments in smoking cessation rates are cost-effective. A second, recently-funded QSAM Translation Project will assess the effectiveness of strategies designed to identify and link smokers who are interested in quitting with appropriate treatments. A previous survey by investigators Melissa Partin, Ph.D. and Anne Joseph, M.D. determined that most smokers who had made an unsuccessful quit attempt using pharmacological therapy were ready to try to quit again within a year. Thus, these patients are ideal for initiatives to provide them with repeat smoking cessation treatment. The RESET Project will use the Pharmacy Benefits Management (PBM) database to identify all veterans at participating facilities who have received pharmacological treatment for smoking cessation in the past year (nicotine replacement therapy and Zyban). These veterans will receive one of two interventions: patient phone call with a tailored provider prompt, or a standard (untailored) patient letter with a generic provider prompt. A third group of veterans will be randomly assigned to a “usual care” control condition.

Here are a few of the exciting areas of QSAM research:

- *GAF ratings are poor predictors of substance abuse patients' outcome:* The Global Assessment of Functioning Scale (GAF) is a standard part of the American Psychiatric Association's diagnostic system. VA policy requires the GAF to be used to help assess mental health patients' level of functioning. However, QSAM research shows that substance abuse patients' clinical diagnoses and psychiatric symptoms are stronger predictors of GAF ratings than their current levels of social and occupational functioning. QSAM is working to identify and implement a better standard measure.
- *Providers Survey:* In a nationwide survey, leaders of VA substance abuse treatment programs endorsed general agreement with practice guideline benefits and disagreement with guideline criticisms. Lack of time, knowledge, and skills were seen as major barriers to implementation of guidelines. Nonsupervisory staff were perceived as neutral or opposed to guidelines, and conflict with program philosophy was not rated as a significant barrier to implementation. Modalities seen as efficacious but not well implemented, such as behavioral marital therapy and smoking cessation interventions, are fertile areas for future quality improvement.
- *Best continuity of care practices for patients with substance use disorders and PTSD:* QSAM analyses indicate that greater duration and intensity of continuing care are related to better substance use, legal and employment outcomes. In addition, QSAM has completed an initial review of probable best substance abuse treatment practices for patients with comorbid substance abuse and PTSD.